• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物不良反应:2007-2009 年欧洲自发报告系统分析。

Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.

机构信息

Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.

出版信息

Eur J Clin Pharmacol. 2012 Jul;68(7):1057-63. doi: 10.1007/s00228-012-1219-4. Epub 2012 Feb 1.

DOI:10.1007/s00228-012-1219-4
PMID:22294060
Abstract

PURPOSE

Spontaneous reporting systems in European countries are crucial for collecting adverse drug reaction (ADR) reports. The aim of this study was to evaluate reporting activity among countries and their strategy to increase the number of reports. We also established the best measure for assessment quantity of reports.

METHODS

This was a retrospective observational study based on questionnaires and annual reports. The most reliable measure of reporting was determined by Spearman correlation coefficients.

RESULTS

Data collected in spontaneous reporting systems in 26 European countries were analysed. In 2007, 2008 and 2009, the average value of reports per year per million inhabitants based on the safety databases of countries was 208, 236, 286, respectively; in comparison, that of Eudra- Vigilance was 311, 453 and 435, respectively. Twelve countries reached a significant level for signal detection of ADRs in 2009. The population-based reporting ratio (PBRR) was correlated to the total expenditure on health (ρ=0.499, p=0.023, n=21), public expenditure on health (ρ=0.477, p=0.035, n=20), density of physicians (ρ=0.336, p=0.136, n=21) and expenditure on pharmaceuticals (ρ=0.365, p=0.114, n=20). Strategies of regulatory authorities to increase reporting were determined.

CONCLUSIONS

The results of this study make several noteworthy contributions regarding national spontaneous reporting systems. The relevance of the PBRR for the measurement reporting activity is clearly supported by the current findings. This study also shows that there is a general trend towards increased reporting activity. This is maintained by regional centres and encouragement of reporting. A further study would be helpful to assess the effectiveness of reporting systems at both the national and European level.

摘要

目的

欧洲国家的自发报告系统对于收集药物不良反应(ADR)报告至关重要。本研究的目的是评估各国的报告活动及其增加报告数量的策略。我们还确定了评估报告数量的最佳指标。

方法

这是一项基于问卷调查和年度报告的回顾性观察研究。通过 Spearman 相关系数确定最可靠的报告衡量指标。

结果

分析了 26 个欧洲国家自发报告系统中收集的数据。2007 年、2008 年和 2009 年,根据各国安全数据库,每年每百万居民的报告平均值分别为 208、236 和 286;相比之下,Eudra-Vigilance 的报告平均值分别为 311、453 和 435。2009 年,有 12 个国家在 ADR 信号检测方面达到了显著水平。基于人口的报告率(PBRR)与卫生总支出(ρ=0.499,p=0.023,n=21)、公共卫生支出(ρ=0.477,p=0.035,n=20)、医生密度(ρ=0.336,p=0.136,n=21)和药品支出(ρ=0.365,p=0.114,n=20)呈正相关。确定了监管机构增加报告的策略。

结论

本研究结果对国家自发报告系统做出了几项值得注意的贡献。当前研究结果明确支持 PBRR 对报告活动测量的相关性。本研究还表明,报告活动呈普遍增加趋势。这是通过区域中心和鼓励报告来维持的。进一步的研究将有助于评估国家和欧洲层面报告系统的有效性。

相似文献

1
Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.药物不良反应:2007-2009 年欧洲自发报告系统分析。
Eur J Clin Pharmacol. 2012 Jul;68(7):1057-63. doi: 10.1007/s00228-012-1219-4. Epub 2012 Feb 1.
2
Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.全球范围内十年来药物不良反应模式分析:来自 VigiBase™ 的自发报告
Drug Saf. 2012 Dec 1;35(12):1171-82. doi: 10.1007/BF03262002.
3
Experiences with adverse drug reaction reporting by patients: an 11-country survey.患者药物不良反应报告经验:11 国调查。
Drug Saf. 2012 Jan 1;35(1):45-60. doi: 10.2165/11594320-000000000-00000.
4
First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.法国首次报告大流行流感疫苗(H1N1)接种后患者不良反应:患者和医务人员报告的比较。
Drug Saf. 2012 Oct 1;35(10):845-54. doi: 10.1007/BF03261980.
5
Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.语言并非“装在盒子里”:评估欧洲葡萄牙语中药物不良反应自发报告与MedDRA®编码之间的差异。
Res Social Adm Pharm. 2015 Sep-Oct;11(5):664-74. doi: 10.1016/j.sapharm.2014.11.009. Epub 2014 Dec 5.
6
Pharmacovigilance systems and databases in Korea, Japan, and Taiwan.韩国、日本和中国台湾的药物警戒系统和数据库。
Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1237-45. doi: 10.1002/pds.2244. Epub 2011 Sep 21.
7
Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.关键药物警戒利益相关者对欧盟患者直接报告药物不良反应的体验及其未来发展前景。
Public Health. 2018 Feb;155:119-128. doi: 10.1016/j.puhe.2017.11.023. Epub 2018 Jan 12.
8
Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).向法国药物警戒系统报告的自发药品不良反应趋势(1986 - 2001年)
Drug Saf. 2005;28(8):731-40. doi: 10.2165/00002018-200528080-00007.
9
Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.患者与医疗保健专业人员自发药物不良反应报告:系统评价。
Drug Saf. 2012 Oct 1;35(10):807-18. doi: 10.1007/BF03261977.
10
Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.药品不良反应报告不足:印度药物警戒面临的一项挑战。
Indian J Pharmacol. 2015 Jan-Feb;47(1):65-71. doi: 10.4103/0253-7613.150344.

引用本文的文献

1
Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles.维洛沙嗪与右旋苯丙胺不良反应谱的真实世界药物警戒比较。
Sci Rep. 2025 Aug 7;15(1):28919. doi: 10.1038/s41598-025-14385-2.
2
Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess.五种抗头颈部鳞状细胞癌药物的不良事件概况:来自世界卫生组织药物警戒数据库VigiAccess的描述性分析
Front Pharmacol. 2025 Jun 24;16:1602276. doi: 10.3389/fphar.2025.1602276. eCollection 2025.
3
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.

本文引用的文献

1
Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK.患者对严重药物不良反应的体验及其对药物的态度:英国史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症幸存者的定性研究。
Drug Saf. 2011 Apr 1;34(4):319-28. doi: 10.2165/11588460-000000000-00000.
2
Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.英国的药物不良反应报告:患者和医疗保健专业人员提交的黄卡报告的回顾性观察比较。
Drug Saf. 2010 Sep 1;33(9):775-88. doi: 10.2165/11536510-000000000-00000.
3
世界卫生组织药物不良反应数据库(WHO-VigiAccess)中三种抗胶质瘤药物的不良反应特征。
Front Pharmacol. 2024 Oct 24;15:1485067. doi: 10.3389/fphar.2024.1485067. eCollection 2024.
4
Educational interventions in pharmacovigilance to improve the knowledge, attitude and the report of adverse drug reactions in healthcare professionals: Systematic Review and Meta-analysis.药物警戒教育干预措施以提高医疗保健专业人员的知识、态度和药物不良反应报告:系统评价和荟萃分析。
Daru. 2024 Jun;32(1):421-434. doi: 10.1007/s40199-024-00508-z. Epub 2024 Mar 1.
5
Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.五种抗TNFɑ药物不良反应的特征分析:来自世界卫生组织药物不良反应数据库(WHO-VigiAccess)的描述性分析
Front Pharmacol. 2023 Jul 24;14:1169327. doi: 10.3389/fphar.2023.1169327. eCollection 2023.
6
Quality of Active versus Spontaneous Reporting of Adverse Drug Reactions in Pediatric Patients: Relevance for Pharmacovigilance and Knowledge in Pediatric Medical Care.儿科患者药物不良反应主动报告与自发报告的质量:对药物警戒及儿科医疗知识的相关性
Pharmaceuticals (Basel). 2022 Sep 14;15(9):1148. doi: 10.3390/ph15091148.
7
Regulation Awareness and Experience of Additional Monitoring among Healthcare Professionals in Finland.芬兰医疗保健专业人员的监管意识及额外监测经验
Healthcare (Basel). 2021 Nov 11;9(11):1540. doi: 10.3390/healthcare9111540.
8
Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.全球 COVID-19 大流行与报告行为 - 对食品和药物管理局不良事件报告系统的分析。
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):707-715. doi: 10.1002/pds.5217. Epub 2021 Mar 17.
9
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.抗精神病药物的致扭转型室性心动过速风险:结合欧洲各地的不良事件报告与药物使用数据
PLoS One. 2013 Nov 20;8(11):e81208. doi: 10.1371/journal.pone.0081208. eCollection 2013.
Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.
提高医院内药物不良反应报告率:法国米迪-庇里牛斯地区药物警戒网络(PharmacoMIP)为期两年的试点研究结果。
Drug Saf. 2010 May 1;33(5):409-16. doi: 10.2165/11319170-000000000-00000.
4
Improving follow-up rates in spontaneous adverse drug reaction reporting: effectiveness of a targeted letter used by a regional centre in the UK.提高自发药物不良反应报告的随访率:英国一个区域中心使用针对性信函的效果。
Drug Saf. 2009;32(12):1135-40. doi: 10.2165/11318940-000000000-00000.
5
Determinants of under-reporting of adverse drug reactions: a systematic review.药品不良反应报告不足的决定因素:一项系统综述
Drug Saf. 2009;32(1):19-31. doi: 10.2165/00002018-200932010-00002.
6
Pharmacovigilance: methods, recent developments and future perspectives.药物警戒:方法、最新进展与未来展望
Eur J Clin Pharmacol. 2008 Aug;64(8):743-52. doi: 10.1007/s00228-008-0475-9. Epub 2008 Jun 4.
7
Use of triage strategies in the WHO signal-detection process.在世卫组织信号检测过程中采用分流策略。
Drug Saf. 2007;30(7):635-7. doi: 10.2165/00002018-200730070-00014.
8
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.患者对疑似药物不良反应的报告:已发表文献及国际经验综述
Br J Clin Pharmacol. 2007 Feb;63(2):148-56. doi: 10.1111/j.1365-2125.2006.02746.x.
9
Under-reporting of adverse drug reactions : a systematic review.药品不良反应报告不足:一项系统评价
Drug Saf. 2006;29(5):385-96. doi: 10.2165/00002018-200629050-00003.
10
An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.对用于决定从英国和美国市场撤回药品的公开传播的安全性证据的评估。
Drug Saf. 2006;29(2):175-81. doi: 10.2165/00002018-200629020-00008.